CVSCVS Health

Health care · Pharmacies · NYSE

Employees: 300,000
Headquarters: Woonsocket, RI
CEO: J. David Joyner
Next results: around Feb 9, 2027

RevenueFY2016–25 $402.1B+7.8% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $1.8B−61.7% FY2024: $4.6B 10-K FY2025 · XBRL Free cash flowFY2016–25 $7.8B+23.4% FY2024: $6.3B 10-K FY2025 · XBRL Operating marginFY2016–25 1.2%−1.1 pts 5.8% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 10, 2026 against Feb 12, 2025

Area	What changed	Source
Risk factors	9 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	1 open-market buy in the last 90 days	Form 4
Filings	4 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 10, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-12. Quoted as filed.

There can be no assurance that we have been able to, or will be able to, adequately prevent, detect, and/or remediate such data security incidents.
10-K, Item 1A

All 9 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +9.1% vs revenue +7.8% (+1.2 pts)
✓
Cash from operations $10.6B vs net income $1.8B (FY ending 2025-12-31)
✓
Inventory +6.3% vs revenue +7.8% (-1.6 pts)
✓
Same auditor in both 10-Ks: Ernst & Young LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No longer listed: Valuation of goodwill for the Government reporting unit. Same as last year: Valuation of health care costs payable
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 6, 2026Buy Shah Prem S (EVP and Group President) bought $2.0M open-market purchase on Nov 6, 2026
Nov 4, 20268-K Quarterly results 8-K item 2.02
Nov 4, 20268-K Regulation FD disclosure 8-K item 7.01
Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on CVS in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CVS/export.csv") into a cell.